Wang Jiyu, Tao Qianshan, Huang Keke, Wang Yangyang, Hu Linhui, Ren Anwen, Wang Huiping, Wan Yang, Li Jinlan, Yi Liuying, Ruan Yanjie, Wanyan Zhixiang, Wu Fan, Zhai Zhimin, Liu Chaohong
Department of Hematology, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonostic Infectious Disease, Huazhong University of Science and Technology, Wuhan, Hubei, China.
J Immunother Cancer. 2025 Jan 7;13(1):e009356. doi: 10.1136/jitc-2024-009356.
Resistance to existing therapies is a major cause of treatment failure in patients with refractory and relapsed B-cell non-Hodgkin's lymphoma (r/r B-NHL). Therapy-induced senescence (TIS) is one of the most important mechanisms of drug resistance.
This study used single-cell RNA sequencing to analyze doxorubicin-induced senescent B-NHL cells. C-C chemokine receptor 7 (CCR7) expression in patients with aggressive B-NHL was assessed using immunohistochemistry and flow cytometry. Lentiviral transfection was used to target CCR7 expression in Raji and SU-DHL-2 cells. Protein localization was visualized through immunofluorescence, while western blotting and co-immunoprecipitation were used to analyze protein expression and interactions. Cell proliferation was measured with the Cell Counting Kit-8 assay, and senescent cells were detected using senescence-associated β-galactosidase staining. The stemness of cells was evaluated through colony and sphere formation assays. Transwell assays assessed cell migration and invasion. Finally, inhibitors GS143 and Y27632 were used to examine the effect of IKBα and ARHGAP/RhoA inhibition on B-NHL-TIS.
Here we identified a distinct group of TIS, composed of memory B-cell population characterized by strong positive expression of CCR7, which was significantly elevated in TIS population compared with normal proliferating and autonomously senescent lymphoma cell populations. Additionally, CCR7 expression was significantly upregulated in patients with r/r B-NHL, and was an independent prognostic factor in B-NHL, with high CCR7 expression being strongly associated with poor prognosis. In vitro results indicated that CCL21 induced migration and invasion of B-NHL cells via CCR7, while blocking CCR7 reduced doxorubicin-induced migration and invasion of these cells. Furthermore, B-NHL-TIS regulated by CCR7 and exhibited enhanced phenotypic and functional stemness features, including the upregulation of stemness markers, increased colony-forming, invasive and migratory capabilities. Mechanistically, blocking CCR7 reversed the stemness characteristics of senescent B-NHL cells by inhibiting the activation of ARHGAP18/IKBα signaling.
Together, TIS promotes the stemness of B-NHL cells via CCR7/ARHGAP18/IKBα signaling activation and targeting CCR7/ARHGAP18 might overcome the chemoresistance of senescent B-NHL cells by inhibiting stemness acquisition and maintenance.
对现有疗法产生耐药性是难治性和复发性B细胞非霍奇金淋巴瘤(r/r B-NHL)患者治疗失败的主要原因。治疗诱导的衰老(TIS)是耐药的最重要机制之一。
本研究使用单细胞RNA测序分析阿霉素诱导衰老的B-NHL细胞。采用免疫组织化学和流式细胞术评估侵袭性B-NHL患者中C-C趋化因子受体7(CCR7)的表达。利用慢病毒转染靶向Raji和SU-DHL-2细胞中的CCR7表达。通过免疫荧光观察蛋白质定位,同时使用蛋白质印迹法和免疫共沉淀法分析蛋白质表达及相互作用。使用细胞计数试剂盒-8检测法测量细胞增殖,并使用衰老相关β-半乳糖苷酶染色检测衰老细胞。通过集落形成和球体形成试验评估细胞的干性。Transwell试验评估细胞迁移和侵袭能力。最后,使用抑制剂GS143和Y27632检测IKBα和ARHGAP/RhoA抑制对B-NHL-TIS的影响。
在此,我们鉴定出一组独特的TIS,由以CCR7强阳性表达为特征的记忆B细胞群体组成,与正常增殖和自主衰老的淋巴瘤细胞群体相比,TIS群体中CCR7显著升高。此外,r/r B-NHL患者中CCR7表达显著上调,且是B-NHL的独立预后因素,CCR7高表达与不良预后密切相关。体外结果表明,CCL21通过CCR7诱导B-NHL细胞迁移和侵袭,而阻断CCR7可减少阿霉素诱导的这些细胞的迁移和侵袭。此外,受CCR7调控的B-NHL-TIS表现出增强的表型和功能干性特征,包括干性标志物上调、集落形成能力增加以及侵袭和迁移能力增强。机制上,阻断CCR7通过抑制ARHGAP18/IKBα信号激活逆转衰老B-NHL细胞的干性特征。
总之,TIS通过CCR7/ARHGAP18/IKBα信号激活促进B-NHL细胞的干性,靶向CCR7/ARHGAP18可能通过抑制干性获得和维持克服衰老B-NHL细胞的化疗耐药性。